Al-Marsad newspaper: The US Food and Drug Administration (FDA) has approved the marketing of the most expensive drug in the world to treat the genetic disorder – Haemophilia B.
The agency gave the green light to Hemgenix from biopharmaceutical company CSL Behring, which set its price at $3.5 million per dose, making it the most expensive treatment in the world.
Hemgenix is given intravenously, once, to adult patients with hemophilia B, an inherited blood disorder that affects mostly men and is caused by a genetic mutation in a protein essential for blood clotting. If left untreated, the condition can cause bleeding that leaks into organs and joints, including the brain, according to The Guardian.
A study found that it cut the number of expected bleeding episodes over the course of a year by more than half, and freed 94% of patients from the need for regular injections to keep things under control.
